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a b s t r a c t
Background: Autologous blood products, such as platelet-rich plasma (PRP) are commercial products
broadly used to accelerate healing of tissues after injuries. However, their content is not standardized and
significantly varies in composition, which may lead to differences in clinical efficacy. Also, the underlying
molecular mechanisms for therapeutic effects are not well understood.
Purpose: A proteomic study was performed to compare the composition of low leukocyte PRP, platelet
poor plasma (PPP), and blood plasma. Pathway analysis of the proteomic data was performed to evaluate
differences between plasma formulations at the molecular level. Low abundance regulatory proteins in
plasma were identified and quantified as well as cellular pathways regulated by those proteins.
Methods: Quantitative proteomic analysis, using multiplexed isotopically labeled tags (TMT labeling) and
label-free tandem mass spectrometry, was performed on plasma, low leukocyte PRP, and PPP. Plasma
formulations were derived from two blood donors (one donor per experiment). Pathway analysis of the
proteomic data identified the major differences between formulations.
Results: Nearly 600 proteins were detected in three types of blood plasma formulations in two experi-
ments. Identified proteins showed more than 50% overlap between plasma formulations. Detected
proteins represented more than 100 canonical pathways, as was identified by pathway analysis. The
major pathways and regulatory molecules were linked to inflammation.
Conclusion: Three types of plasma formulations were compared in two proteomic experiments. The most
represented pathways, such as Acute Phase Response, Coagulation, or System of the Complement, had
many proteins in common in both experiments. In both experiments plasma sample sets had the same
direction of biochemical pathway changes: up- or down-regulation. The most represented biochemical
pathways are linked to inflammation.
© 2020, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
1. Introduction
In the past two decades commercial formulations of platelet-
rich plasma (PRP) have been increasingly used in orthopedic and
other medical applications to augment the healing of soft tissue
injuries or chronic inflammation [1e4]. PRP therapy is an appealing
treatment due to its autologous nature, anti-microbial properties,
and relatively easy preparation. Many authors have reported
enhanced healing after PRP injection, but a lack of efficacy has also
been widely reported [3e6].
The idea behind PRP usage is to increase the concentration of
activated platelets at an area of damaged tissue, and thus achieve a
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many-fold increase of concentration of growth factors and cyto-
kines released by platelets. While PRP treatment has never been
reported as harmful, the clinical efficacy of the procedure remains
variable, probably due to the varied composition and properties of
PRP formulations [4,7e10]. Factors of variability include but are not
limited to: 1) medical conditions and ages of patients, 2) manu-
facturers of PRP devices, 3) different protocols used for PRP prep-
aration, 4) different content of cells, e.g. thrombocytes, leukocytes,
and levels of cell-secreted regulatory molecules in PRP, because of
the preceding. Proteomic analysis can address some of these dif-
ferences in PRP composition, and potentially relate them to the
specific steps of the protocols that are being used for their
generation.
Several research groups observed negative biological effects in
cell culture of too high numbers of platelets, as well as high
numbers of lymphocytes in human blood plasma products
[4,5,10e13]. For example, synoviocytes [14] and human ligament
fibroblasts [5] treated with such PRP showed increased MMP
secretion, and proinflammatory response [4,15].
Successful usage of leucocyte-rich PRP was also demonstrated
in vitro and in vivo [16]. A number of clinical trials showed the
effectiveness of leucocyte-rich PRP in treating orthopedic injuries
such as gluteal tendinopathy, plantar fasciitis, tennis elbow,
compared to alternative options [17e21]. Both leucocyte-rich and
leucocyte-poor types of PRP are broadly used to treat musculo-
skeletal injuries.
According to Pifer et al. [5] “future studies are necessary to
understand anabolic, catabolic, and inflammatory factors in PRP
and how they affect various pathologic states in soft tissues.” In
agreement with this, Murray writes in an editorial that “optimal
PRP formulations should be established for specific indications” [8].
Other authors have expressed similar views; it is possible that a
range of certain cell types, as well as levels of regulatory proteins in
PRP, have tissue-specific optima and need to be controlled. Such
optimization could be critical in assisting healing of different tissue
types, but the tissue-specific ranges remain to be established
[3,8e10,13,22]. Enhanced concentration of certain regulatory mol-
ecules, e.g. growth factors and cytokines, released by cells could
lead to suboptimal levels of inflammation, fibrotic, apoptotic, and
catabolic processes [23,24].
Proteomic analysis is a suitable technology to assess the protein
content of plasma formulations during method development. Mass
spectrometry-based proteomic methods are the most common
technologies for the large-scale study of proteins and peptides on a
picomole, or even femtomole level [25,26].
The aim of this paper is to quantify and characterize the protein
composition in 1) leukocyte poor PRP and in 2) platelet poor plasma
(PPP). As a pilot study, we evaluated only plasma formulations
derived from two blood donors; the next phase of investigation
would include several donors of blood plasma, up to ten, which
would be processed into PRP and PPP for further proteomic anal-
ysis. This would allow applying biostatistical analysis to mass-
spectral results. Proteomic data were further analyzed using In-
genuity Pathway Analysis (IPA) and the DAVID resources, which
allowed the comparison of plasma formulations on molecular and
pathway levels [27,39].
2. Materials and Methods
2.1. Blood processing: preparation of PRP and other plasma
fractions
After Institutional Review Board approval3, two healthy donors
provided 50 mL of blood, which was processed to produce
leukocyte-poor plasma formulations. Blood was drawn in a clinical
laboratory.
Blood was processed using Pure PRP kit and a matching
centrifuge from EmCyte Corp., with sodium citrate as anticoagulant
[7,10]. Two plasma formulations were prepared: 1) traditional
platelet-rich plasma, PRP, and 2) platelet poor plasma, PPP, ac-
cording to the EmCyte manual for Pure PRP kit. Platelet enrichment
or removal was controlled by an automatic complete blood count
(CBC), whichwas performed for each blood donor for blood plasma,
PRP and PPP using 1 mL of each fraction at Stanford Clinical Labo-
ratory. White blood cells and platelets numbers are presented for
each plasma fraction for donors in Table 1.
Aliquots of these fractions were immediately prepared for pro-
teomic analysis, 10 mcl each. These aliquots were flash-frozen in
liquid nitrogen after addition of protease inhibitor cocktail
(#78429, Thermo Fisher Scientific) and stored at 80 C.
2.2. Sample preparation for mass-spectrometry
Plasma fractions from two human donors were analyzed by
mass spectrometry, using the experimental protocols described
below. Please see Fig. 1 for the Scheme of procedures.
2.3. Multiple Affinity Removal System, MARS
MARS system (# 5188e6560 and #5188e5254, Agilent) was
used for immunodepletion of 14 high-abundance proteins in 10mcl
aliquots of all plasma samples: albumin, IgG, antitrypsin, IgA,
transferrin, haptoglobin, fibrinogen, alpha 2-macroglobulin,
alpha1-acid glycoprotein, IgM, apolipoprotein AI, apolipoprotein
AII, complement C3, and transthyretin. Processing of tenmicroliters
of each plasma formulation resulted in one ml of flow-through (FT)
List of abbreviations
C18 A resin for reversed-phase chromatography
DTT Dithiothreitol, a reducing reagent also known as
Cleland's reagent
ECM Extracellular matrix
FT Flow-through fractions in sample separation
IPA Ingenuity Pathway Analysis software
LC-MS/MS Liquid chromatography with tandem mass
spectrometry
LTQ Orbitrap Elite mass spectrometer, Thermo
Scientific
ppm Parts per million
PPP Platelet-poor plasma
PRP Platelet-rich plasma
RP Reverse phase fractionation
SpeedVac Vacuum concentrator
Swiss-Prot Manually annotated, non-redundant protein
sequence database, freely accessible
TEAB Triethylammonium bicarbonate
TCEP Reducing agent tris (2-carboxyethyl) phosphine
TMT Tandem mass tags
UniProt Database of protein sequence and functional
information, freely accessible
UPLC Ultra-performance liquid chromatography
3 The study's protocol was approved by institutional review board (IRB). Research
Compliance Office, Stanford University, 3000 El Camino Real; Five Palo Alto Square,
Palo Alto, CA 94306.
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sample, a depleted plasma sample, containing medium- and low-
abundance proteins (~5% of initial protein amount). These
depleted (FT) samples were concentrated using a 3MWCO Amicon
centrifugal filter unit (UFC500324, EMD Millipore) to 25 mcl, and
the buffer was replaced with 50 mM NH4HCO3. After depletion
from high-abundance proteins, medium- and low-abundance
proteins of plasma samples were digested in solution with an
enzyme mixture of trypsin and LysC (details are in the paragraphs
for Experiments I, and II), followed by LC-MS/MS analysis.
2.4. Experiment I. Preparation of three plasma samples for label-
free MS analysis
Plasma, PRP, and PPP, 10 mcl of each, were depleted of abundant
proteins (Fig. 1). Flow through (FT) fractions were concentrated,
and after buffer exchange to 50 mM NH4HCO3, reduced and alky-
lated, followed by trypsin digestion. For reduction and alkylation,
20 mL of ProteaseMax solution, which is a surfactant to solubilize
proteins (Promega, V2072), was added to 25 mL of depleted plasma
samples in 50 mM NH4HCO3. Then to reduce disulfide bonds in
proteins, 1.6 mL of 500 mM DTT stock was added to each sample,
followed by incubation at 55 C for 30 min. For alkylation of the
resulting thiol groups, 3.2 mL of 1 M acrylamide was added to each
sample, followed by incubation at room temperature for 30 min.
After that, for proteolytic digestion Trypsin/Lys-C mix was added at
a 1:50 ratio (Promega V5071, Trypsin/Lys-C Mix, Mass Spec Grade)
on ice, and samples were incubated at 37 C overnight. Tryptic
digest was quenched by adding 5 mL of 50% formic acid in water.
Samples were spun at 10,000 g for 10 min and desalted in a Stage
Tip purification step. For sample desalting of label-free peptides we
used reversed phase MicroSpin Columns, TARGA C18 SEM SS18R
from NEST according to the operating instructions. Samples were
concentrated in a vacuum centrifuge (SpeedVac Concentrator
Savant from Thermo Scientific) and submitted to tandem mass
spectrometry (LC-MS/MS).
2.5. Experiment I. Mass spectrometry data acquisition and database
searches
Samples were analyzed by LC-MS/MS using a Nanoacquity
UPLC system (Waters, Milford, MA) interfaced to a LTQ-Orbitrap
Elite mass spectrometer (Thermo Scientific, San Jose, CA). Chro-
matography was performed using an Easy-Spray 75 um  150 mm
C18 column (Thermo Fisher, ES800) at a flow rate of 400 nl/min.
The 60 min gradient ran from 2 to 25% of buffer B in 39 min, then
to 70% B in a further 5 min, before returning to 2% B in 1 min to
equilibrate for the next run. Buffer A was 0.1% formic acid; buffer B
was acetonitrile in 0.1% formic acid. Survey scans were performed
from m/z 350e1500, with ions measured in the Orbitrap at a
resolution setting of 60 K. The top six multiply charged ions were
selected for fragmentation analysis by resonant excitation
collision-induced dissociation and measured in an ion trap. Pre-
cursors were then dynamically excluded from re-selection for 30 s.
Raw data were analyzed using Protein Prospector v5.19.23 (PMID:
18653769). Searches were performed against the human entries in
a Swiss-Prot database downloaded on May 9th, 2016, with
concatenated randomized sequences (20,200 entries searched) to
allow estimation of the false discovery rate [28]. Peptides were
assumed to be fully tryptic. Precursor ion tolerance was set
at ± 10 ppm and fragment tolerance was set at ± 0.6 Da. Propio-
namide modification of cysteines was considered as a constant
modification; variable modifications considered were methionine
and tryptophan oxidation, deamidation of asparagines, pyro-
glutamate formation from peptide N-terminal glutamines, pro-
tein N-terminal methionine removal, acetylation, and combina-
tions thereof. Results for each sample were reported at the 1e2%
false discovery rate at the protein level. Quantitation was per-
formed using spectral counting. Pathway analysis of protein lists
for this data set was performed using Ingenuity Pathway Analysis
database, IPA (39).
2.6. Experiment II. Protein quantitation using multiplexed
isotopically labeled tags (tandem mass tags, TMT)
Plasma, PRP, and PPP plasma aliquots, 10 mcl of each, were
depleted of abundant proteins (2.2 and 2.3). Protein concentration
was measured with 660 nm Protein Assay Kit (Pierce, # 22,662).
Reduction and alkylation were performed according to the manual
for TMT 6-plex Isobaric Mass Tag Labeling Kit (Thermo Sci., #
90,061). Reducing agent TCEP (tris (2-carboxyethyl) phosphine)
was dissolved at 200 mM in 100 mM triethylammonium bicar-
bonate (TEAB). Samples were incubated at 55 C for 1 h with 5 mcl
of 200 mM TCEP. For the reaction of alkylation 2.5 mcl of 750 mM
iodoacetamide was added per sample. Incubation processed for
30 min at room temperature in vials protected from light, followed
by adding 6x volume of cold acetone and precipitation overnight.
Acetone-precipitated protein pellets were dissolved in 100 mL of
100 mM TEAB. For trypsin digestion in solution 20 ml ProteaseMax
solution (Promega, V2072) was added to each sample. Trypsin/Lys-
C mix, 0.5 mcg/1 mcl per sample, was then added at a 1:50 ratio
(Promega V5071, Trypsin/Lys-C Mix, Mass Spec Grade) and incu-
bated at 37 C overnight. TMT 6-plex isobaric mass tag peptide
labeling: TMT Label Reagents (with mass tags in the range
126e131 Da; Thermo Sci. # 90,061) were dissolved in 40 mL of
anhydrous acetonitrile and added to each sample. The reaction
proceeded for 1 h at room temperature and was quenched with
8 mL of 5% hydroxylamine followed by 15 min incubation. TMT
labeled samples were combined into one sample in a new tube. The
combined sample was desalted and fractionated off-line using
high-pH Reversed-Phase Peptide Fractionation cartridge (Pierce,
#84868) to produce eight peptide fractions, which were concen-
trated in a vacuum centrifuge, and submitted to tandem mass
spectrometry.
2.7. Liquid chromatography mass spectrometry (LC-MS)
Each of the eight high-pH fractionated peptide pools was
reconstituted in mobile phase A, and peptides loaded onto a self-
packed C18 reversed phase column (C18, 2.4 mM, Dr. Maish, Ger-
many) 35 cm in length. The UPLC was the ACQUITY UPLC M-Class
System fromWaters, where mobile phase Awas 0.2% formic acid in
water and mobile phase B was 0.2% formic acid in acetonitrile. For
Table 1
Platelet and white blood cell (WBC) count for donor samples used for proteomic
study. All numbers represent cells x 103 per ml of blood fraction, except the row
“Platelet enrichment in PRP” representing fold change compared to plasma.
Blood donor number I II
WBC in blood 4.4 4.5
WBC in plasma 0.8 0.9
WBC in PRP 0.6 0.3
Platelets in blood plasma 152 264
Platelets in PRP 685 472
Platelets in PPP 6 6
Platelet enrichment in fold change by PRP preparation 4.5 1.8
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each fraction a 180 min separation gradient was used, where the
starting mobile phase B percentage was 4% ramped up linearly to
42%, followed by a wash and re-equilibration step. The flow rate
was 300 nl/min. The mass spectrometer was an Orbitrap Fusion,
where peptides were ionized in positive mode at a spray voltage of
1800 V. The methodology used was a MS3 (synchronous precursor
scan SPS) method where the isobaric peptides were fragmented
first in the ion-trap followed by a “notch” event isolating (0.7Da)
the 5 most intense fragment ions. These ions were then subse-
quently fragmented using HCD and transferred to the Orbitrap,
where the scan range was set at 120e500 m/z with a resolution
setting of 60,000. Charge states analyzed were 2þ-6þ where the
AGC settings for the two MSMS events were 50,000 and 100,000
ions, respectively. A dynamic exclusion list was used, based on
precursor mass ± 10 ppm and an exclusion duration of 90 s. Formic
acid, trifluoroacetic acid, acetonitrile, and water were of LC-MS
grade from Pierce.
2.8. Peptide identification and isobaric reporter ion quantification
Raw files containing MS/MS spectra were qualified using Pre-
view software (Protein Metrics, San Carlos, CA) to validate peptide
observations and overall quality before proceeding to peptide
assignment. Peptide assignment and protein inference were made
using Byonic MS/MS search engine v2.6.49 (Protein Metrics, San
Carlos, CA) as a node in Proteome Discoverer (Thermo Scientific,
San Jose, CA), which was used to assign quantitative ratios for
isobaric-tagged samples. Samples were searched against the Uni-
prot Homo sapiens protein database, containing isoforms (January
2016). Assignments were made to semi-tryptic peptides, with
12 ppm mass tolerances for precursor ions, 0.4 Da tolerances for
fragment ions, and 12 ppm tolerances for MS3 reporter ion mea-
surements. All data were validated using a standard 1% false dis-
covery rate as introduced by Gygi and coworkers using a reverse-
decoy technique [28]. The resulting mass spectral data, including
peptide spectral matches and assigned proteins, were exported for
visualization and statistical characterization. Pathway analysis of
protein lists for this set of data was performed using both IPA and
David databases (David db.) [27,39].
2.9. Pathway analysis software
Ingenuity Pathway Analysis (IPA, QIAGEN) software was used to
analyze and interpret all sets of experimental data. Protein lists and
mass-spectral peak counts in Experiment I, or ratios for TMT-
labeled samples in Experiment II were used as input 39]. David
database, version 6.7, was also applied for pathway analysis using
gene list as an input in Experiment II (2.6e2.8) [27].
Venn diagrams were made using the software tool available at
the URL in reference [40].
3. Results
3.1. Quantitative proteomic analysis of blood plasma, PRP, and PPP
formulations
3.1.1. Experiment I (blood donor # 1)
About 320 proteins were detected in total in three types of
samples: plasma, PRP, and PPP. For the complete list of proteins in
these formulations, and their relative expression, presented as a
heat map, see Supplemental Materials, Table I. About 50% of pro-
teins were found in common in all three fractions (Fig. 2). In a
comparison of fractions, about 130 proteins with various important
functions, such as calcium-binding proteins SPARC (osteonectin)
calmodulin and calumenin, enzymes catalase and superoxide dis-
mutase, platelet glycoprotein V and platelet factor 4, type 1
collagen, talin and transforming growth factor beta-1, were detec-
ted in traditional PRP fraction, but not in PPP (Table 2, Fig. 2). Fifteen
proteins were detected only in PPP fraction, but not in plasma, or
PRP. This group included functionally important aminopeptidase N,
hepatocyte growth factor-like protein, von Willebrand Factor and
selenoprotein P (Table 2). Nine proteins were detected only in
plasma sample (Fig. 2 and Supplementary Table I), List of proteins in
plasma formulations, and a heat map of their relative expression).
1. Plasma samples, 10 µl = 500 µg of protein, were filtered through 0.2 µm membrane from MARS kit, and applied on Agilent antibody-based 
cartridge to remove the14 high-abundance proteins and to produce flow through fraction, FT, containing low-abundance proteins. FT results in ~ 
5% of 500 µg of starting total protein (in 10 µl of plasma)  and equals ~ 25 µg of protein in 1 ml of buffer.
2. Protein concentration in FT fraction up to ~25 µg/25 µl using 3MWCO filter. It followed by buffer exchange: wash of FT fraction with 100 µl 
of 50 mM NH4HCO3, 3x times.
VARIED PART: Proteomic Experiment II. Donor II.    Samples: plasma, PRP and PPP .
3. Reduction of disulfide bonds by TCEP in TEAB, followed by alkylation in iodoacetamide/TEAB.
4. Acetone precipitation overnight and re-dissolving in 100mM TEAB buffer.
5. Trypsin/Lys C digest overnight.
6. TMT 6-plex Isobaric Mass Tag peptide labeling.
7. TMT-quenching reagent: 50% hydroxylamine. 
8. Three TMT-labeled samples (derived from plasma, PRP and PPP ) were combined in one, and additionally fractionated “off-line”.
9. Pierce Reversed-Phase Peptide Fractionation Kit resulting in eight samples to submit to LC-MS/MS.
VARIED PART: Proteomic Experiment I. Donor I.    Samples: plasma, PRP and PPP
3. Reduction of disulfide bonds by adding 0.5 µl of 500 mM DTT stock to each sample; incubation at 55˚C for 30 minutes.
4. Alkylation: 1 µl of 1M acrylamide was added to each sample and incubated at RT for 30 minutes.
5. Trypsin digest: 0.5 µg/1µl of mix, trypsin and Lys C enzymes was added per sample and incubated at 37˚C overnight. Digest was quenched by  
adding 2µl of 50% formic acid.
6. Three samples (plasma, PRP and PPP) desalting using reverse phase spin columns: MicroSpin RP C18 _ SEM SS18R from NEST. SpeedVac to  
concentrate sample.
7. Submitting samples (plasma, PRP and PPP) to LC-MS/MS.
VARIED PART. Proteomic Experiment I.
VARIED PART. Proteomic Experiment II.
SAMPLE PREPARATION IN EXPERIMENTS I, AND II. COMMON PART:
Fig. 1. Scheme of common procedures and differences between sample processing in two experiments. Details are in the text, subsections 2.3e2.8.
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About 50% of identified proteins were found in all three plasma
fractions or shared between two plasma samples. It is infeasible to
list and describe all of the quantitative and qualitative differences in
the identified proteins amongst all plasma formulations
(Supplementary Table I. List of proteins in plasma formulations, and
a heat map of their relative expression). Therefore, we applied In-
genuity pathway analysis, IPA, which revealedmore than a hundred
biochemical pathways, with typically 20e40 proteins identified in
each pathway per experimental group. Top canonical pathways and
levels of their activation, based on IPA-generated heat map, are
shown in Table 3 and Supplementary Table II (Full list of canonical
pathways identified by IPA for the Experiment I, including proteins
in each pathway for each blood plasma sample).
List of all pathways detected, including lists of proteins for each
pathway, can be found in the Supplementary Table II. Heatmap for
pathways detected in plasma fractions in Experiment I can be
found in Supplementary Table III. Selected major pathways iden-
tified by IPA in plasma samples with their components are shown
in Table 4.
3.1.2. Experiment II (blood donor # 2)
Samples of plasma, PRP and PPP in this proteomic experiment
were TMT-labeled for quantification after a tryptic/Lys C enzymatic
digest step, as described in Material and Methods. About 450 pro-
teins were determined altogether in these three fractions by Byonic
software (as described in Material and Methods). Results of mass
spectral analysis were presented as a ratio between levels of pro-
teins in PRP and PPP compared to protein levels in plasma. A full list
of proteins for Experiment II and a heat map of individual protein
levels’ changes in plasma fractions can be found in Supplementary
Table IV.
The DAVID database search engine recognized 20 proteins out of
450 proteins in this data set as being released by platelet alpha
granules. Also, serine proteases (>20) and serpins, their inhibitors
(>20) were detected. Several acute phase pentaxin proteins were
identified: serum amyloid P-component and C-reactive protein,
which was decreased in PPP compared to PRP and plasma (in this
order). Another detected acute phase protein is hemopexin; its
synthesis is induced after inflammation. Multiple components of
the complement system were significantly enhanced in PRP and
PPP compared to plasma sample. Among proteins that changed in
level, several extracellular matrix-receptor interactors were
identified.
Individual protein changes in the plasma formulations can be
seen in the Supplementary Table IV.
The following major pathways were identified using IPA and
DAVID databases in all plasma fractions.
1) acute inflammatory response, represented by more than 20
proteins, according to both the IPA and DAVID databases; 2) wound
healing, approximately 30 proteins per type of plasma; 3) com-
plement activation, about 30 proteins per plasma sample; 4)
leukocyte migration, about 10 proteins per sample; 5) cell structure
and motility, about 30 proteins in each type of plasma, and many
more processes, or canonical pathways. Both databases returned
similar results in pathway detection, with a better overlap in major
pathways.
A list of the top canonical pathways determined by IPA, and the
major components of these pathways detected in Experiment II in
all three plasma fractions can be seen in Table 4.
Several proteins were highly abundant in PPP compared to PRP:
fibronectin (FN), a notable multifunctional glycoprotein of the
extracellular matrix that binds to integrins, collagens, fibrin, pro-
teoglycans, etc. FN is known for its involvement in acute phase
reactions, cell motility, wound healing, fibril formation, and more
[29]. Other abundant proteins were fibulin, selenoprotein P, throm-
bospondin (a multifunctional protein of blood platelet alpha-gran-
ules). Examples of proteins that were in low concentration in both,
PRP and PPP, compared to plasma include angiotensinogen, anti-
thrombin III, catalase, platelet basic protein and several other pro-
teins (Supplementary Table IV. Full list of proteins for the
Experiment II and a heat map of relative protein levels).
3.2. Regulatory proteins identified in plasma fractions by mass-
spectrometry or predicted by IPA in proteomic experiments I and II
In both experiments we detected several growth factors and
cytokines. These regulatory molecules are important for cell stim-
ulating effects of PRP, and their relative levels in plasma formula-
tions, are presented in Table 5.
The Comparison Analysis mode within the IPA program allows
the prediction of the upstream regulators for individual pathways.
Although most of these molecular regulators were not detected
directly by mass-spectral analysis, due to their levels in plasma
below the technical detection threshold, such prediction was
possible based on quantitative changes of proteins in our data sets
(Table 6).
The top regulator in both data sets was IL6, so we have provided
an illustration only for its protein interactions (Fig. 3). In the
Experiment II in IL6 pathway, apolipoprotein B, fibrinogen alpha
chain and heat shock protein were more than two-fold up-regu-
lated in PPP and PRP compared to plasma, while alpha-1-
antichymotrypsin, angiotensinogen, and thrombospondin-1 were
significantly down-regulated in PPP and PRP compared to plasma
(Supplementary Table IV).
Other top predicted regulators that appeared similar in two
proteomic experiments were HNF1 and HNF4 (transcriptional ac-
tivators of the homeobox family), TGFbeta1, IL-1b, TNFa and SMAD3
(Table 6).
4. Discussion
Quantitative proteomics analysis facilitates in-depth analysis of
biological systems. Such analysis of plasma content would aid in
understanding effects of plasma formulations, controlling their
production or targeted modification for therapeutic applications.
Here we present proteomic analysis of plasma formulations,
including low leukocyte PRP and PPP, which exerted multi-fold
biological effects on myoblast differentiation and proliferationFig. 2. Experiment I. Venn diagram comparison of three plasma fractions.
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in an earlier study, as well as on protein biomarker expression
[7].
We used sets of samples from two donors in two different
experiments: different in sample preparation procedure (Fig. 1)
followed by data acquisition, and protein identification in two
mass-spectrometry centers, which used different instruments
and software (see Materials and Methods, subsections 2.2;
2.4e2.8). The enormous dynamic range of protein concentra-
tions in biological fluids is an analytical challenge for detecting
important low-abundance proteins, which is broadly addressed
by the proteomic community [25,26,30]. Therefore, we used two
independent workflows: sample processing before mass-spectral
analysis using TMT labeling of peptides versus label-free peptide
identification as well as instrumentation, and proteomic
software.
In all, nearly 600 proteins were detected in plasma formulations
in two proteomic experiments. Plasma, PRP and PPP fractions had
approximately 50% overlap in protein identification (Fig. 2 and
Table 2). It appears that more proteins were identified in PRP than
in the original plasma, which is related to the technical specifics of
the method of mass-spectrometry and problem of the protein dy-
namic range in blood plasma (more than 10 orders of magnitude;
therefore high abundance proteins mask low abundance proteins)
[25,26].
Table 2
Proteins detected by mass-spectral analysis only in one of the plasma fractions in Experiment I, which reflects differences in plasma formulations.
# of proteins in plasma
fraction
Proteins detected by mass-spectrometry analysis in only one plasma fraction
Proteins detected only in PRP
(129):
Vinculin; Alpha-enolase; Moesin; Radixin; Actin; alpha cardiac muscle 1; 14-3-3 proteins zeta/delta, beta/alpha and protein epsilon; Heat
shock cognate 71 kDa protein and Heat shock 70 kDa protein 1 A; Alpha-actinin-1; Alpha-actinin-4; Zyxin; Peptidyl-prolyl cisetrans
isomerase A; Cofilin-1; Profilin-1; Caldesmon; Adenylyl cyclase-associated protein 1; Hemoglobin subunits beta and delta; Pyruvate kinase
PKM; Tropomyosin alpha-4 and beta chains; Glyceraldehyde-3-phosphate dehydrogenase Triosephosphate isomerase; Protein disulfide-
isomerase A3; Calreticulin; Catalase; Protein deglycase DJ-1 Phosphoglycerate kinase 1; Carbonic anhydrase 2; Thrombospondin-1; Serum
deprivation-response protein; Fructose-bisphosphate aldolase A; Pleckstrin; Rho GDP-dissociation inhibitor 2; Platelet glycoprotein V; Ras
suppressor protein 1; Vasodilator-stimulated phosphoprotein; L-lactate dehydrogenase A chain; Rab GDP dissociation inhibitor alpha and
beta; L-lactate dehydrogenase B chain; Coagulation factor V; Glucose-6-phosphate isomerase; Microtubule-associated protein RP/EB family
member 2; Adenylate kinase isoenzyme 1; Peptidyl-prolyl cisetrans isomerase FKBP1A; PDZ and LIM domain protein 1; Calmodulin;
Alpha-endosulfine; Ras-related protein Rap-1b; Fermitin family homolog 3; SH3 domain-binding glutamic acid-rich-like protein 3;
Annexin A5; Phosphoglycerate mutase 1; Rho GTPase-activating protein 1; Nucleosome assembly protein 1-like 1; Protein disulfide-
isomerase A6; Peroxiredoxin-6; Glutathione S-transferase P; Eukaryotic translation initiation factor 4H; Ras-related protein Rab-7a; WAS/
WASL-interacting protein family member 1; Serglycin; Purine nucleoside phosphorylase; SH3 domain-binding glutamic acid-rich-like
protein; Chloride intracellular channel protein 1; Reticulon-4; Phosphoglucomutase-1; Thymidine phosphorylase;
Phosphatidylethanolamine-binding protein 1; Flavin reductase (NADPH); Plasminogen activator inhibitor 1; Talin-1; Peroxiredoxin-1 and
-2; Rho GDP-dissociation inhibitor 1; Nidogen-1; Trans-Golgi network integral membrane protein 2; Coactosin-like protein; Polymeric
immunoglobulin receptor; Src substrate cortactin; D-tyrosyl-tRNA (Tyr) deacylase 1; Prothymosin alpha;
Beta-parvin; Neurogranin; Ig kappa chain V-III region SIE; Ig gamma-2 chain C region;
Phosphatidylcholine-sterol acyltransferase; Small ubiquitin-related modifier 3; SPARC (Osteonectin); Microtubule-associated protein RP/
EB family member 1; Integrin alpha-IIb; Collagen alpha-1(I) chain; Heparanase; Transforming growth factor beta-1; Malate
dehydrogenase, cytoplasmic; Adenine phosphoribosyltransferase; Peptidyl-prolyl cisetrans isomerase FKBP3; Actin-related protein 2/3
complex subunit 1 B; Calumenin; Cysteine and glycine-rich protein 1; SH3 domain-binding glutamic acid-rich-like protein 2; Septic-7;
Peptidyl-prolyl cisetrans isomerase NIMA-interacting 1; Superoxide dismutase [CueZn]; Basement membrane-specific heparan sulfate
proteoglycan core protein; Intraflagellar transport protein 140 homolog; S-arrestin; Serine/threonine-protein phosphatase 2 A activator;;
Ubiquitin-conjugating enzyme E2 variant 1; Platelet factor 4; Target of Nash-SH3; Endonuclease domain-containing 1 protein; Protein
CDV3 homolog; Cyclin-dependent kinase 2-associated protein 1; Ubiquitin-conjugating enzyme E2 N; Receptor-type tyrosine-protein
phosphatase; Dynein heavy chain 1, axonemal; Ig alpha-1 chain C region; Tight junction protein ZO-2; Amyloid beta A4 protein
Proteins detected only in PPP
(15):
Aminopeptidase N; Proteoglycan 4; Selenoprotein P; Intercellular adhesion molecule 2; Ectonucleotide pyrophosphatase/
phosphodiesterase family member 2; Neogenin; Hepatocyte growth factor-like protein; Hornerin; von Willebrand factor; Desmoglein-2;
Granzyme K; Apolipoprotein D; Lysosome-associated membrane glycoprotein 2; Lysozyme C; Zinc finger and BTB domain-containing
protein 46
Proteins detected only in
plasma (9):
Transforming growth factor-beta-induced protein ig-h3; Mimecan; Neuropilin-1; Insulin-like growth factor-binding protein 6; CD44
antigen; Ezrin; Grainyhead-like protein 1 homolog; THAP domain-containing protein 5; Mannosyl-oligosaccharide 1,2-alpha-mannosidase
IC
Table 3
Activation of top canonical pathways in plasma formulations, based on IPA data. Pathways are listed in the order (decreasing) of statistical significance.
Canonical pathway Plasma PRP PPP
1 Acute phase Response Signaling High Low High
2 Complement System High Low Medium/high
3 Coagulation System Medium Low High
4 LXR/RXR Activation Medium Low Medium/high
5 FXR/RXR Activation Medium Medium/Low Medium/high
6 Actin Cytoskeleton Signaling Low Medium/high Low
7 Production of Nitric Oxide and Oxygen Species in Macrophages Low Low Medium
8 Clathrin-mediated Endocytosis Signaling Low Low Low
9 Integrin signaling Low Medium/high Low
10 Glycolysis and gluconeogenesis Low High Low
11 IL-12 signaling and Production in Macrophages Low Low Medium
12 RhoA signaling Low Medium Low
13 Hematopoiesis from Pluripotent Stem Cell Signaling Low Medium Low
14 Leukocyte Extravasation Signaling Low High Low
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We did not provide similar Venn diagram (as in Experiment I;
3.1.1.) for proteins identified in plasma fractions in Experiment II, as
proteomic software presented results as quantitative ratios for each
protein in those plasma fractions and original blood plasma
(Supplementary Table IV). Although experiments I and II were
different from each other (Fig. 1), more than 200 proteins were
found in common in both experiments, which is a good repro-
ducibility for proteomic results and a solid justification of MS data
that were used for the pathway analysis. Furthermore, both ex-
periments, I and II, delivered very similar results of IPA software
analysis, and identified activation or reduction of same major
biochemical pathways, and often the same proteins (Tables 3-6 and
Supplementary Table II, III and V).
Multiple Affinity Removal System, MARS, was used for immu-
nodepletion of 14 high-abundance so-called ‘house-keeping pro-
teins’ in plasma samples which are listed in the Materials and
Methods. While a few additional proteins that bind to these may
also get depleted, as the same treatment was applied to all samples,
we expect the same proteins to be depleted in each of them.
Therefore it should not affect the comparison between samples
[30]. Also, major pathways detected by IPA and David Database in
plasma samples are represented by 20 or many more proteins, and
Table 5
Regulatory proteins: growth factors, chemokines and their receptors identified in plasma fractions in proteomic experiments I and II. Indices 1,2 refer to the number of
experiment where protein was detected.
Growth factors or cytokines Regulation (Y down, or
[up)
Biological effects of a factor (based on the annotation in the UniProt database)
1 1Complement C5 No significant change
between fractions
Chemokine that stimulates the locomotion of polymorphonuclear leukocytes and
directs their migration toward sites of inflammation
2 1,2 Hepatocyte growth factor activator &
hepatocyte growth factor-like protein
↑ in PPP Hepatocyte growth factor receptor signaling pathway
3 1,2 Insulin-like growth factor-binding protein
complex
No significant change Involved in proteineprotein interactions that result in protein complexes, receptor-
ligand binding or cell adhesion.
4 2 Isoform 2 of Insulin-like growth factor II No significant change Growth-promoting activity; in vitro mitogen. Exhibits osteogenic properties by
increasing osteoblast mitogenic activity
5 1,2 Pigment epithelium-derived factor ↓ in PPP in Experiment I Potent inhibitor of angiogenesis
6 1,2 Platelet basic protein ↑ in PRP CXCR chemokine receptor binding; positive regulation of cell migration
7 1Platelet factor 4 ↑ in PRP Chemotactic for neutrophils and monocytes. Inhibits endothelial cell proliferation
8 1,2 TGF beta-induced protein ↓in PRP, and absent in PPP
in Experiment I
Plays a role in cell adhesion and perhaps in cellecollagen interactions
9 1,2 Transforming growth factor beta 1 ↑ in PRP Multifunctional cytokine that controls cell growth, proliferation, differentiation, and
apoptosis
Table 4
Top canonical pathways and their components identified by IPA in Experiment II in plasma fractions.
# Canonical pathway Gene Names




2 aComplement System SERPING1,MASP2,C9,C1QA,C1QC,C1QB,C8A,C4A/C4B,C1R,MBL2,C7,CFB,CFI,CFH,CD59,C3,
C4BPB,C1S,MASP1,C5,C4BPA,C8B,C6,C8G,C2
3 aCoagulation System KNG1,F12,PROC,F13A1,VWF,F7,F2,SERPINF2,FGG,SERPIND1,PLG,F10,KLKB1,
SERPINC1,F9,F8,PROS1,SERPINA5,F5,SERPINA1,FGB,FGA,A2M,F13B




5 FXR/RXR Activation KNG1,APOE, APOB,APOA4,APOA2,APOC4,AMBP,C9,APOC2,C4A/C4B,PON1,HPR,
LCAT, ITIH4,SERPINA1,AGT,TTR,HPX,APOM,C3,AHSG, FETUB,SAA4,A1BG,SERPINF2,APOL1,ALB,
APOA1,ORM1,TF,APOC1,ORM2,PLTP,FGA,CLU,RBP4,APOC3
6 Actin Cytoskeleton Signaling KNG1,FN1,PFN1,CFL1,ARPC1B,ACTB,RDX,TLN1,GSN,F2,ACTA2,CD14,
ACTG2,LBP,VCL,ACTN4,TMSB10/TMSB4X,ACTC1,ACTA1,ACTN1,MSNs





8 Clathrin-mediated Endocytosis Signaling APOE, APOA4,APOB,LPA,ACTB, APOA2,APOC2,F2,PON1,ALB,APOA1,
TF,ACTA2,SERPINA1,ACTG2,ACTC1,ACTA1,CLU,RBP4,APOC3
9 Integrin signaling RAP1B,ITGA2B,PFN1,ARPC1B,ACTB,TLN1,GSN,WIPF1,ACTA2,ZYX,ACTG2,ACTN4,
VCL,ACTC1,CTTN, ACTA1,VASP, ACTN1
10 Glycolysis and gluconeogenesis PGK1,ENO1,GPI,PGK2,TPI1,PGAM1,PKM,ALDOA, GAPDH;,MDH1
11 IL-6 signaling COL1A1,CD14,LBP,A2M,IL6ST,CRP,CD14
12 IL-12 Signaling and Production in Macrophages APOE, APOM,APOA4,APOB,
APOC4,APOA2,MST1,APOC2,SAA4,APOL1,PON1,ALB,APOA1,ORM1,APOC1,
ORM2,SERPINA1,CLU,RBP4,APOC3
13 RhoA signaling PFN1,ARPC1B,CFL1,ACTA2,ACTB, SEPT7,RDX,ACTG2,ACTC1,ARHGAP1,ACTA1,MSN
14 Leukocyte Extravasation Signaling RAP1B,VCAM1,ACTB,RDX,MMP2,WIPF1,ACTA2,CDH5,ACTN4,VCL,ACTG2,ARHGAP1,
ACTC1,CTTN, ACTN1,ACTA1,VASP,MSN
a These pathways were significantly enhanced in PPP compared to PRP. Heatmap for pathways detected in plasma fractions (that illustrate quantitative differences between
pathways in plasma, PRP and PPP samples) can be found in Supplementary Table V.
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removal of one or two proteins from the pathway should not affect
its detection and relative representation.
Platelet removal in PPP apparently eliminated or changed con-
centration of some regulatory proteins: pigment epithelium-
derived factor, platelet basic protein, platelet factor 4, several
Caþþ binding proteins, such as caldesmon, calmodulin, calreticulin
and calumenin, multifunctional Heat shock protein Hsp 70 (Tables
2, 5 and Supplementary Table I and IV), as well as some yet un-
identified factors, which lie below a technical threshold of mass-
spectral detection. However, using IPA software, we were able to
predict presence of such regulatory factors based on pathway
analysis (Table 6). Differences in levels of these regulatory proteins,
their presence, or absence, will affect numerous cell types and
biological processes, like tissue healing, levels of inflammation, cell
differentiation and proliferation [1,7]. However, establishing roles
for individual factors that were present in changed concentration in
PPP, compared to traditional PRP or plasma lies beyond the scope of
this work; it would require a higher number of patient samples
with laborious sample screening and validation.
We observed significant changes in canonical biochemical
pathways between three plasma fractions. In both experiments,
the major pathway, Acute Phase Response Signaling, was
increased in PPP compared to PRP (Tables 3 and 4; Supplementary
Table III and V). Acute Phase Response pathway is directly linked
to inflammation; it is regulated by cytokines. This pathway in-
cludes plasma proteins, like C-reactive protein, serum amyloid A,
transthyretin, fibronectin and others (Table 4 and Supplementary
Table II ), which change many-fold in response to injury [23,31,32].
A member of S100 protein family, hornerin, was enhanced in PPP
formulation. It is known for its role inwound healing, and possible
regulatory role in inflammatory immune response and prolifera-
tion [33].
Other top pathways detected by IPA: Coagulation, System of the
Complement and LXR/RXR are also linked to inflammation through
common pathway members [34e37]. These processes were also
Fig. 3. IPA Comparison Analysis predicted IL6 as a top upstream regulator for protein
expression changes in two proteomic data sets (for two different blood donors) 41.
Table 6
List of top predicted upstream regulators in plasma fractions generated by IPA software in Experiments I and II.
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activated in PPP compared to PRP in both experiments (Tables 3 and
4; Supplementary Table III and V).
The next regulatory pathways were only slightly activated in
PPP compared to PRP: IL-12 Signaling and Production of Nitric
Oxide (NO), while among the down-regulated pathways in PPP
were: Clathrin-mediated Endocytosis Signaling, Actin Cytoskeleton
Signaling and STAT3 pathway (Table 4, Supplementary Table II, III
and V). Two other detected pathways, Wnt Signaling and PDGF
Signaling, participate in switching cells between cell proliferation
and differentiation [16,38]. However, we did not reliably trace
changes for two last pathways due to the low level of their com-
ponents. It is well established that both processes, differentiation
and proliferation, are critical for tissue regeneration; cell switching
between these processes is finely regulated and intersects with cell
cycle pathways.
It was encouraging to see very close results in IPA analysis in
both experiments despite individual variability between blood
donors, and technical settings in mass spectrometry experiments.
Repetitiveness of predicted regulatory molecules, many of which
are known for pro-inflammatory properties: IL6, IL-1b, IL13, IFNG,
TNFa, and more between two experiments was also encouraging
(Table 6). Among predicted by IPA software upstream regulators for
plasma fractions, IL6 was identified as the top regulator in both
experiments (Table 6, Fig. 3). It is a potent inducer of the acute
phase response, among a wide range of biological functions. IL6
affects B-cells, T-cells, hepatocytes, hematopoietic progenitor cells
and cells of nervous system; it also acts as a myokine (22, 23).
Despite partial (~50%) overlap in protein identification between
similar plasma fractions (reproducibility is an inherent limitation of
the proteomic methods chosen), the major identified pathways and
the directions of their changes were closely reproduced in two
experiments.
5. Conclusion
This is a comparative biochemical proteomic study of platelet
rich plasma, a commercial product for accelerated healing. In total,
nearly 600 proteins were detected in plasma formulations in two
proteomic experiments. They represented more than 100 canonical
pathways, as was identified by IPA pathway analysis. The top
pathways, such as Acute Phase Response, Coagulation, or System of
the Complement, had many pathway members in common in both
experiments. In both experiments plasma sample sets had pre-
dominantly same direction of biochemical pathway changes: acti-
vation or down-regulation.
Experiments I and II were different from each other in blood
samples (donors I and II), in sample processing (TMT labeling of
peptides in Experiment II), in instrumentation (different mass-
spectrometers), and in proteomic data processing software.
Nevertheless, more than 200 proteins were found in common in
both experiments, which was a solid justification of proteomic re-
sults, which were used for the following pathway analysis. Main
biochemical pathways detected by IPA in both experiments are
linked to inflammation.
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